Discovery of kidney cancer driver could lead to new treatment strategy

In a study published in the journal Science, researchers led by UNC Lineberger's Qing Zhang, Assistant Professor in the departments of Pathology & Laboratory Medicine and Pharmacology, suggest that ZHX2 is a potential new therapeutic target for clear cell renal cell carcinoma, which is the most common type of kidney cancer.

Discovery of kidney cancer driver could lead to new treatment strategy click to enlarge Qing Zhang, PhD

July 19, 2018

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.

More than 90 percent of the most common type of kidney cancer have a genetic change that leads to the loss of an important tumor suppressor gene called VHL. In a study published in the journal Science, researchers identified a new downstream effect of this genetic change that is helping to drive kidney cancer: They found that a protein called ZHX2 over-accumulates in these cells and helps to turn on other signals involved in cancerous growth. Their findings suggest that ZHX2 is a potential new therapeutic target for clear cell renal cell carcinoma, which is the most common type of kidney cancer.  

read the full article by Laura Oleniacz on SOM Newsroom...